PL1765362T3 - Kompozycje i sposoby do leczenia chorób związanych z neowaskularyzacją - Google Patents
Kompozycje i sposoby do leczenia chorób związanych z neowaskularyzacjąInfo
- Publication number
- PL1765362T3 PL1765362T3 PL05804888T PL05804888T PL1765362T3 PL 1765362 T3 PL1765362 T3 PL 1765362T3 PL 05804888 T PL05804888 T PL 05804888T PL 05804888 T PL05804888 T PL 05804888T PL 1765362 T3 PL1765362 T3 PL 1765362T3
- Authority
- PL
- Poland
- Prior art keywords
- signaling inhibitor
- compositions
- methods
- neovascular diseases
- trprs
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 101000640990 Arabidopsis thaliana Tryptophan-tRNA ligase, chloroplastic/mitochondrial Proteins 0.000 abstract 4
- 102000002501 Tryptophan-tRNA Ligase Human genes 0.000 abstract 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 4
- 230000011664 signaling Effects 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000000964 angiostatic effect Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 230000006459 vascular development Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
- C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
- C12Y601/01002—Tryptophan-tRNA ligase (6.1.1.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57715604P | 2004-06-04 | 2004-06-04 | |
| US58527304P | 2004-07-01 | 2004-07-01 | |
| US65580105P | 2005-02-24 | 2005-02-24 | |
| PCT/US2005/019800 WO2005117954A2 (en) | 2004-06-04 | 2005-06-06 | Compositions and methods for treatment of neovascular diseases |
| EP05804888A EP1765362B1 (en) | 2004-06-04 | 2005-06-06 | Compositions and methods for treatment of neovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1765362T3 true PL1765362T3 (pl) | 2012-08-31 |
Family
ID=35463352
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05804888T PL1765362T3 (pl) | 2004-06-04 | 2005-06-06 | Kompozycje i sposoby do leczenia chorób związanych z neowaskularyzacją |
| PL12002028T PL2484365T3 (pl) | 2004-06-04 | 2005-06-06 | Kompozycje i sposoby leczenia chorób neowaskularnych |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12002028T PL2484365T3 (pl) | 2004-06-04 | 2005-06-06 | Kompozycje i sposoby leczenia chorób neowaskularnych |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7528106B2 (pl) |
| EP (3) | EP2484365B1 (pl) |
| JP (1) | JP4943324B2 (pl) |
| KR (1) | KR101224368B1 (pl) |
| AT (1) | ATE551060T1 (pl) |
| AU (1) | AU2005249586B2 (pl) |
| CA (1) | CA2568750C (pl) |
| DK (2) | DK2484365T3 (pl) |
| ES (3) | ES2450541T3 (pl) |
| MX (1) | MXPA06014092A (pl) |
| PL (2) | PL1765362T3 (pl) |
| PT (2) | PT1765362E (pl) |
| WO (1) | WO2005117954A2 (pl) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7528106B2 (en) * | 2004-06-04 | 2009-05-05 | The Scripps Research Institute | Compositions and methods for treatment of neovascular diseases |
| US20060024288A1 (en) * | 2004-08-02 | 2006-02-02 | Pfizer Inc. | tRNA synthetase fragments |
| US8282921B2 (en) * | 2004-08-02 | 2012-10-09 | Paul Glidden | tRNA synthetase fragments |
| RU2401124C2 (ru) * | 2005-02-24 | 2010-10-10 | Дзе Скриппс Рисерч Инститьют | Реваскуляризация ишемической ткани сетчатки и способ ее скрининга |
| ES2338400B1 (es) * | 2008-05-06 | 2011-09-14 | David Benet Ferrus | Conjunto de moleculas antiangiogenicas y su uso. |
| WO2009152247A2 (en) | 2008-06-11 | 2009-12-17 | Atyr Pharma, Inc | Thrombopoietic activity of tyrosyl-trna synthetase polypeptides |
| EP2310498A1 (en) * | 2008-06-26 | 2011-04-20 | Atyr Pharma, Inc. | Compositions and methods comprising glycyl-trna synthetases having non-canonical biological activities |
| US20120004185A1 (en) | 2009-02-27 | 2012-01-05 | Atyr Pharma, Inc. | Polypeptide structural motifs associated with cell signaling activity |
| ES2742251T3 (es) | 2009-03-16 | 2020-02-13 | Pangu Biopharma Ltd | Composiciones y procedimientos que comprenden variantes de splicing de histidil-tarn sintetasa que tienen actividades biológicas no canónicas |
| US20100235734A1 (en) * | 2009-03-16 | 2010-09-16 | Bas Ording | Methods and Graphical User Interfaces for Editing on a Multifunction Device with a Touch Screen Display |
| EP2414513B1 (en) | 2009-03-31 | 2015-10-28 | Atyr Pharma, Inc. | Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities |
| US8828395B2 (en) | 2009-12-11 | 2014-09-09 | Atyr Pharma, Inc. | Antibodies that bind tyrosyl-tRNA synthetases |
| WO2011072266A2 (en) * | 2009-12-11 | 2011-06-16 | Atyr Pharma, Inc. | Aminoacyl trna synthetases for modulating hematopoiesis |
| CN102821784B (zh) | 2009-12-11 | 2016-09-21 | Atyr医药公司 | 用于调节炎症的氨酰tRNA合成酶 |
| AU2011248625B2 (en) | 2010-04-26 | 2017-01-05 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase |
| CN103096910A (zh) | 2010-04-27 | 2013-05-08 | Atyr医药公司 | 与苏氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| WO2011139799A2 (en) | 2010-04-27 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases |
| EP2563911B1 (en) | 2010-04-28 | 2021-07-21 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases |
| JP5991963B2 (ja) | 2010-04-29 | 2016-09-14 | エータイアー ファーマ， インコーポレイテッド | バリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| AU2011248490B2 (en) | 2010-04-29 | 2016-11-10 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases |
| AU2011248357B2 (en) | 2010-05-03 | 2017-02-23 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases |
| AU2011248355B2 (en) | 2010-05-03 | 2017-01-19 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Arginyl-tRNA synthetases |
| WO2011140132A2 (en) | 2010-05-03 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases |
| JP6008841B2 (ja) | 2010-05-03 | 2016-10-19 | エータイアー ファーマ， インコーポレイテッド | メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| WO2011140267A2 (en) | 2010-05-04 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex |
| JP6008843B2 (ja) | 2010-05-04 | 2016-10-19 | エータイアー ファーマ， インコーポレイテッド | グルタミル−プロリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| CA2799197C (en) | 2010-05-14 | 2019-10-29 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases |
| WO2011146410A2 (en) | 2010-05-17 | 2011-11-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases |
| JP6046607B2 (ja) | 2010-05-27 | 2016-12-21 | エータイアー ファーマ， インコーポレイテッド | グルタミニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| AU2011261486B2 (en) | 2010-06-01 | 2017-02-23 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-tRNA synthetases |
| CN103108649B (zh) | 2010-07-12 | 2016-10-12 | Atyr医药公司 | 与组氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物 |
| AU2011289831C1 (en) | 2010-07-12 | 2017-06-15 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
| US8999321B2 (en) | 2010-07-12 | 2015-04-07 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
| CA2804278C (en) | 2010-07-12 | 2021-07-13 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases |
| CA2808539C (en) | 2010-08-25 | 2021-05-25 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases |
| US9399770B2 (en) | 2010-10-06 | 2016-07-26 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tryptophanyl-tRNA synthetases |
| WO2013022982A2 (en) | 2011-08-09 | 2013-02-14 | Atyr Pharma, Inc. | Pegylated tyrosyl-trna synthetase polypeptides |
| WO2013086216A1 (en) | 2011-12-06 | 2013-06-13 | Atyr Pharma, Inc. | Improved aspartyl-trna synthetases |
| WO2013086228A1 (en) | 2011-12-06 | 2013-06-13 | Atyr Pharma, Inc. | Pegylated aspartyl-trna synthetase polypeptides |
| EP2797959A4 (en) | 2011-12-29 | 2015-08-26 | Atyr Pharma Inc | ASPARTYL-tRNA synthetase FC CONJUGATES |
| DK2814514T3 (en) | 2012-02-16 | 2017-12-18 | Atyr Pharma Inc | Histidyl tRNA synthetases for the treatment of autoimmune and inflammatory diseases |
| ES2847383T3 (es) | 2013-03-15 | 2021-08-03 | Atyr Pharma Inc | Conjugados de Fc-histidil-ARNt sintetasa |
| KR101899591B1 (ko) * | 2015-02-26 | 2018-09-17 | 재단법인 의약바이오컨버젼스연구단 | 트립토파닐 티알엔에이 합성효소를 유효성분으로 포함하는 감염성 염증 질환의 치료 또는 예방용 조성물 및 면역증강용 조성물 |
| EP3612215B1 (en) | 2017-04-20 | 2024-08-28 | aTyr Pharma, Inc. | Compositions for treating lung inflammation |
| WO2023001288A1 (zh) * | 2021-07-23 | 2023-01-26 | 百奥泰生物制药股份有限公司 | 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用 |
| CN116515827B (zh) * | 2023-03-20 | 2024-12-10 | 复旦大学附属眼耳鼻喉科医院 | 用于治疗年龄相关性黄斑变性的活性成分、药物组合物和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4405378A1 (de) | 1994-02-19 | 1995-08-24 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| DE4415310A1 (de) | 1994-04-30 | 1995-11-02 | Merck Patent Gmbh | Cyclopeptide |
| DE4429461A1 (de) | 1994-08-19 | 1996-02-22 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| EP0710657B1 (de) | 1994-11-02 | 1998-08-26 | MERCK PATENT GmbH | Adhäsionsrezeptor-Antagonisten |
| DE19516483A1 (de) | 1995-05-05 | 1996-11-07 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
| US5767071A (en) | 1995-06-07 | 1998-06-16 | Ixsys Incorporated | Sevenmer cyclic peptide inhibitors of diseases involving αv β3 |
| DK1920773T3 (da) * | 1996-11-05 | 2011-03-28 | Childrens Medical Center | Thalidomid og dexamethason til behandling af tumorer |
| US6559144B2 (en) | 1997-02-13 | 2003-05-06 | Merck Patent Gesellschaft Mit | Bicyclic amino acids |
| DE19705450A1 (de) * | 1997-02-13 | 1998-08-20 | Merck Patent Gmbh | Bicyclische aromatische Aminosäuren |
| DE19755800A1 (de) | 1997-12-16 | 1999-06-17 | Merck Patent Gmbh | Cyclopeptidderivate |
| DE19831710A1 (de) | 1998-07-15 | 2000-01-20 | Merck Patent Gmbh | Diacylhydrazinderivate |
| CA2371824A1 (en) | 1999-02-20 | 2000-08-24 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | .beta.-alanine derivatives |
| DE19916837A1 (de) | 1999-04-14 | 2000-10-19 | Merck Patent Gmbh | Dibenzoazulenderivate |
| DE19932796A1 (de) | 1999-07-14 | 2001-01-18 | Merck Patent Gmbh | Diacylhydrazinderivate |
| DE19939980A1 (de) | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Inhibitoren des Integrins alphavbeta¶3¶ |
| EP2258834B1 (en) * | 2000-03-31 | 2015-09-23 | The Scripps Research Institute | Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis |
| KR20030061390A (ko) * | 2000-11-01 | 2003-07-18 | 메르크 파텐트 게엠베하 | 안구 질환 치료용 조성물 및 방법 |
| US20040029788A1 (en) * | 2000-11-01 | 2004-02-12 | Hans-Markus Bender | Methods and compositions for the treatment of diseases of the eye |
| AU2002220265A1 (en) * | 2000-11-03 | 2002-05-15 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| IL152420A0 (en) * | 2001-02-23 | 2003-05-29 | Novartis Ag | Novel oncolytic adenoviral vectors |
| KR100869914B1 (ko) * | 2001-02-23 | 2008-11-21 | 더 스크립스 리서치 인스티튜트 | 혈관 형성 조절에 유용한 트립토파닐-ｔＲＮＡ 신세타제기원 폴리펩타이드 |
| AU2002332430A1 (en) * | 2001-07-26 | 2003-02-17 | Novartis Ag | Methods of treating neuropilin-mediated diseases |
| EA006746B1 (ru) * | 2001-11-09 | 2006-04-28 | Айтек Фармасьютикалз | Способы лечения глазных неоваскулярных заболеваний |
| NZ535100A (en) * | 2002-03-20 | 2008-04-30 | Univ Florida | RAAV vector compositions and methods for the treatment of choroidal neovascularization |
| US7893033B2 (en) * | 2002-05-06 | 2011-02-22 | Board Of Regents, The University Of Texas System | Targeting proteins to deliver therapeutic or diagnostic reagents |
| EP2281885A1 (en) * | 2003-08-27 | 2011-02-09 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
| EP1711172A4 (en) * | 2003-12-23 | 2008-07-16 | Univ Pennsylvania | COMPOSITIONS AND METHODS FOR COMBINATION THERAPY OF ILLNESSES |
| US7528106B2 (en) * | 2004-06-04 | 2009-05-05 | The Scripps Research Institute | Compositions and methods for treatment of neovascular diseases |
-
2005
- 2005-06-06 US US11/145,587 patent/US7528106B2/en not_active Expired - Fee Related
- 2005-06-06 AT AT05804888T patent/ATE551060T1/de active
- 2005-06-06 KR KR1020077000238A patent/KR101224368B1/ko not_active Expired - Fee Related
- 2005-06-06 CA CA2568750A patent/CA2568750C/en not_active Expired - Fee Related
- 2005-06-06 DK DK12002028.4T patent/DK2484365T3/da active
- 2005-06-06 ES ES12002027.6T patent/ES2450541T3/es not_active Expired - Lifetime
- 2005-06-06 JP JP2007515675A patent/JP4943324B2/ja not_active Expired - Fee Related
- 2005-06-06 PT PT05804888T patent/PT1765362E/pt unknown
- 2005-06-06 PL PL05804888T patent/PL1765362T3/pl unknown
- 2005-06-06 EP EP12002028.4A patent/EP2484365B1/en not_active Expired - Lifetime
- 2005-06-06 EP EP12002027.6A patent/EP2484364B1/en not_active Expired - Lifetime
- 2005-06-06 PL PL12002028T patent/PL2484365T3/pl unknown
- 2005-06-06 MX MXPA06014092A patent/MXPA06014092A/es active IP Right Grant
- 2005-06-06 DK DK05804888.5T patent/DK1765362T3/da active
- 2005-06-06 ES ES12002028.4T patent/ES2439390T3/es not_active Expired - Lifetime
- 2005-06-06 AU AU2005249586A patent/AU2005249586B2/en not_active Ceased
- 2005-06-06 ES ES05804888T patent/ES2382661T3/es not_active Expired - Lifetime
- 2005-06-06 EP EP05804888A patent/EP1765362B1/en not_active Expired - Lifetime
- 2005-06-06 WO PCT/US2005/019800 patent/WO2005117954A2/en not_active Ceased
- 2005-06-06 PT PT120020284T patent/PT2484365E/pt unknown
-
2009
- 2009-05-04 US US12/387,507 patent/US20090285792A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2484365A1 (en) | 2012-08-08 |
| DK2484365T3 (da) | 2013-12-02 |
| PL2484365T3 (pl) | 2014-03-31 |
| MXPA06014092A (es) | 2007-03-15 |
| EP1765362B1 (en) | 2012-03-28 |
| CA2568750C (en) | 2014-05-27 |
| PT1765362E (pt) | 2012-06-04 |
| EP1765362A2 (en) | 2007-03-28 |
| WO2005117954A3 (en) | 2006-10-12 |
| EP2484364B1 (en) | 2014-02-19 |
| KR101224368B1 (ko) | 2013-01-22 |
| KR20070041498A (ko) | 2007-04-18 |
| AU2005249586B2 (en) | 2010-12-23 |
| AU2005249586A1 (en) | 2005-12-15 |
| EP2484364A1 (en) | 2012-08-08 |
| EP2484365B1 (en) | 2013-10-02 |
| EP1765362A4 (en) | 2010-02-24 |
| US7528106B2 (en) | 2009-05-05 |
| US20060003933A1 (en) | 2006-01-05 |
| ES2382661T3 (es) | 2012-06-12 |
| JP4943324B2 (ja) | 2012-05-30 |
| US20090285792A1 (en) | 2009-11-19 |
| WO2005117954A2 (en) | 2005-12-15 |
| CA2568750A1 (en) | 2005-12-15 |
| ES2439390T3 (es) | 2014-01-22 |
| DK1765362T3 (da) | 2012-05-14 |
| PT2484365E (pt) | 2013-12-12 |
| ATE551060T1 (de) | 2012-04-15 |
| ES2450541T3 (es) | 2014-03-25 |
| JP2008501718A (ja) | 2008-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1765362T3 (pl) | Kompozycje i sposoby do leczenia chorób związanych z neowaskularyzacją | |
| SG166775A1 (en) | Combinations and modes of administration of therapeutic agents and combination therapy | |
| WO2005063745A3 (en) | Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof | |
| MXPA05013642A (es) | Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer. | |
| TW200626159A (en) | Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor | |
| LUC00011I2 (pl) | ||
| IL244727A0 (en) | Methods and preparations using immunomodulatory compounds for the treatment and management of cancer and other diseases | |
| MXPA05012155A (es) | Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades. | |
| NZ592039A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| MX336710B (es) | Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades. | |
| WO2005046593A3 (en) | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| EP1503748A4 (en) | DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY | |
| TW200501946A (en) | Pharmaceutical composition for the treatment of schizophrenia in a patient with overweight | |
| MXPA06002939A (es) | 6-aril-7-haloimidazo[1,2-a]pirimidinas como agentes contra el cancer. | |
| IL147416A (en) | Combined modalities for improved cancer treatment |